Because the airway epithelia of CF patients are exposed to the combination of all the factors present in SMM or BALF, as opposed to a defined inflammatory factor, the use of SMM and BALF represents a highly translational model to test the impact of the CF airway inflammatory milieu on the efficacy of CFTR modulators. Here, CFTR is linked to cystic fibrosis.